Optima Health (OPT) Q4 2026 TU earnings summary

Executive summary

• Full year adjusted EBITDA for FY26 expected to be approximately 10% ahead of market expectations, reflecting strong H2 performance.

• Strategic progress continues toward medium-term targets of £200 million revenue and £40 million adjusted EBITDA.

• Recent acquisition of PAM completed on 26 March 2026, enhancing market position and operational synergies.

Financial highlights

• FY26 adjusted EBITDA expected to exceed market consensus of £18.1 million by about 10%.

• Other operating income of £2.3 million recognized in H1 FY26 and £2.4 million in H2 FY26.

Outlook and guidance

• Enlarged group positioned to capitalize on growing market opportunities and achieve medium-term EBITDA targets.

• Full trading update to be provided later in Q2 2026.